Peginterferon beta-1a concentrations in breast milk of lactating multiple sclerosis patients.
Breast milk
Multiple sclerosis
Peginterferon beta-1a concentrations
Journal
Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
30
08
2021
revised:
08
02
2022
accepted:
19
02
2022
pubmed:
10
3
2022
medline:
18
5
2022
entrez:
9
3
2022
Statut:
ppublish
Résumé
Peginterferon beta-1a is an interferon beta-1a formulation that has been pegylated, resulting in a longer half-life than other interferon beta formulations. We examined concentrations of peginterferon beta-1a in breast milk of lactating patients with multiple sclerosis (MS) receiving peginterferon beta-1a as their postpartum disease-modifying therapy. After completion of titration to a full dose of peginterferon beta-1a and following a single full dose peginterferon beta-1a injection (125 µg), breast milk samples (≥10 mL) were collected by 5 women on days 1-14 post injection. Peginterferon beta-1a concentrations in breast milk samples were measured by a qualified enzyme-linked immunosorbent assay (detection threshold: 15 pg/mL). Mean and median daily concentrations and median maximum concentration (C After receiving a single full dose peginterferon beta-1a injection, the maximum breast milk concentration recorded in an individual patient was 126.2 pg/mL (0.00013 µg/mL) on day 6. The remaining patients all had maximum breast milk concentrations <72 pg/mL. The geometric mean of C Minimal concentrations of peginterferon beta-1a were detected in the breast milk samples. These findings may be useful for clinicians considering postpartum MS treatment options.
Sections du résumé
BACKGROUND
BACKGROUND
Peginterferon beta-1a is an interferon beta-1a formulation that has been pegylated, resulting in a longer half-life than other interferon beta formulations. We examined concentrations of peginterferon beta-1a in breast milk of lactating patients with multiple sclerosis (MS) receiving peginterferon beta-1a as their postpartum disease-modifying therapy.
METHODS
METHODS
After completion of titration to a full dose of peginterferon beta-1a and following a single full dose peginterferon beta-1a injection (125 µg), breast milk samples (≥10 mL) were collected by 5 women on days 1-14 post injection. Peginterferon beta-1a concentrations in breast milk samples were measured by a qualified enzyme-linked immunosorbent assay (detection threshold: 15 pg/mL). Mean and median daily concentrations and median maximum concentration (C
RESULTS
RESULTS
After receiving a single full dose peginterferon beta-1a injection, the maximum breast milk concentration recorded in an individual patient was 126.2 pg/mL (0.00013 µg/mL) on day 6. The remaining patients all had maximum breast milk concentrations <72 pg/mL. The geometric mean of C
CONCLUSION
CONCLUSIONS
Minimal concentrations of peginterferon beta-1a were detected in the breast milk samples. These findings may be useful for clinicians considering postpartum MS treatment options.
Identifiants
pubmed: 35263702
pii: S2211-0348(22)00215-2
doi: 10.1016/j.msard.2022.103700
pii:
doi:
Substances chimiques
Polyethylene Glycols
3WJQ0SDW1A
Interferon-beta
77238-31-4
peginterferon beta-1a
I8309403R0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
103700Informations de copyright
Copyright © 2022. Published by Elsevier B.V.